Cboe UK EUR

Almirall, S.A. (ALME.XC)

Compare
9.59 0.00 (0.00%)
As of July 23 at 2:20:19 PM GMT+1. Market Open.
Loading Chart for ALME.XC
DELL
  • Previous Close 9.59
  • Open 9.66
  • Bid 9.32 x --
  • Ask 9.45 x --
  • Day's Range 9.59 - 9.59
  • 52 Week Range 8.54 - 9.66
  • Volume 66
  • Avg. Volume 0
  • Market Cap (intraday) 2.046B
  • Beta (5Y Monthly) 0.36
  • PE Ratio (TTM) --
  • EPS (TTM) -0.19
  • Earnings Date Feb 17, 2025 - Feb 21, 2025
  • Forward Dividend & Yield 0.18 (1.92%)
  • Ex-Dividend Date May 17, 2024
  • 1y Target Est --

Almirall, S.A., a biopharmaceutical company, engages in the purchase, manufacture, storage, and sale of skin-health medicines in Europe, the Middle East, the United States, Asia, and Africa. The company offers its products for skin diseases comprising actinic keratosis, atopic dermatitis, alopecia areata, skin cancer, psoriasis, onychomycosis, vitiligo, hidradenitis suppurativa, oncodermatology, acne, orphan indications, and rare skin diseases, as well as for alimentary tract and metabolism; antiinfectives for systemic use; cardiovascular, musculo-skeletal, respiratory, and nervous system; dermatologicals; genito urinary system and sex hormones; immunostimulants; and systematic hormonal preparations. It has a multi-target alliance with Etherna to research and develop new mRNA-based therapies for severe skin diseases, including non-melanoma skin cancer. The company was formerly known as Laboratorios Almirall, S.A. and changed its name to Almirall, S.A. in May 2009. Almirall, S.A. was founded in 1943 and is headquartered in Barcelona, Spain.

www.almirall.com

1,904

Full Time Employees

December 31

Fiscal Year Ends

Recent News: ALME.XC

View More

Performance Overview: ALME.XC

Trailing total returns as of 12/23/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

ALME.XC
14.53%
IBEX 35...
13.36%

1-Year Return

ALME.XC
14.53%
IBEX 35...
13.25%

3-Year Return

ALME.XC
7.26%
IBEX 35...
35.37%

5-Year Return

ALME.XC
28.17%
IBEX 35...
18.35%

Compare To: ALME.XC

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: ALME.XC

View More

Valuation Measures

Annual
As of 10/18/2024
  • Market Cap

    1.74B

  • Enterprise Value

    1.74B

  • Trailing P/E

    --

  • Forward P/E

    16.26

  • PEG Ratio (5yr expected)

    0.30

  • Price/Sales (ttm)

    2.04

  • Price/Book (mrq)

    1.38

  • Enterprise Value/Revenue

    2.18

  • Enterprise Value/EBITDA

    16.40

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -4.71%

  • Return on Assets (ttm)

    0.99%

  • Return on Equity (ttm)

    -2.99%

  • Revenue (ttm)

    953.49M

  • Net Income Avi to Common (ttm)

    -44.87M

  • Diluted EPS (ttm)

    -0.19

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    343.1M

  • Total Debt/Equity (mrq)

    23.63%

  • Levered Free Cash Flow (ttm)

    114.48M

Research Analysis: ALME.XC

View More

Company Insights: ALME.XC

Research Reports: ALME.XC

View More